廣告
香港股市 將在 5 小時 51 分鐘 開市
  • 恒指

    16,248.97
    -351.49 (-2.12%)
     
  • 國指

    5,743.78
    -112.66 (-1.92%)
     
  • 上證綜指

    3,007.07
    -50.31 (-1.65%)
     
  • 道指

    37,871.00
    +135.89 (+0.36%)
     
  • 標普 500

    5,063.07
    +1.25 (+0.02%)
     
  • 納指

    15,898.83
    +13.82 (+0.09%)
     
  • Vix指數

    18.03
    -1.20 (-6.24%)
     
  • 富時100

    7,820.36
    -145.17 (-1.82%)
     
  • 紐約期油

    85.46
    +0.05 (+0.06%)
     
  • 金價

    2,411.40
    +28.40 (+1.19%)
     
  • 美元

    7.8319
    +0.0034 (+0.04%)
     
  • 人民幣

    0.9235
    -0.0005 (-0.05%)
     
  • 日圓

    0.0504
    -0.0001 (-0.26%)
     
  • 歐元

    8.3173
    +0.0017 (+0.02%)
     
  • Bitcoin

    62,811.62
    -535.08 (-0.84%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     

'Well-Established' Eye Health Company Bausch + Lomb Gets Outperform Rating From This Analyst

  • RBC Capital markets initiated coverage on Bausch + Lomb Corp (NYSE: BLCO) with an Outperform rating and a $22 price target.

  • The analysts see B+L as a diversified ophthalmology company with strong brand equity, reaping the rewards of over $2 billion of investment since 2018 through several new product launches and expected margin improvement.

  • The company is a well-established eye health company operating in the $50 billion vision care, surgical, and pharmaceutical markets.

  • RBC notes that some gaps in its product suite should be resolved over ~24 months, permitting B+L to better leverage its high brand equity and achieve or may exceed its targeted 4-5% revenue growth over time.

  • "We recognize the shares may be volatile in the near-term based on the outcome of the BHC Xifaxan patent trial (decision likely by mid-August), which will potentially influence the timing/decision regarding the expected 80% BLCO distribution by Bausch Health Companies Inc (NYSE: BHC)." RBC writes.

  • Price Action: BLCO shares are down 3.79% at $15.48 during the market session on the last check Tuesday.

See more from Benzinga

廣告

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.